Compare ARK Genomic Revolution ETF (ARKG) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KB Financial Group, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while KB Financial Group, Inc. trades at $125 (market cap $42.55B). The key difference: KB Financial Group, Inc. pays a 2.55% dividend while ARK Genomic Revolution ETF pays none, and KB Financial Group, Inc. is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | KB | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $123.19 |
52-Week Low | $23.09 | $77.50 |
Market Cap | — | $42.55B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
KB Financial Group (KB) trades at $123.19, up 6.78% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals from moving averages, though oscillators suggest caution with RSI near overbought levels. Fundamentally, revenue grew to $21.23T in 2025 with a net income margin of 27.82%, supported by diversification into non-banking segments. Analyst sentiment is mixed with a 33% buy rating, while recent news highlights dividend potential and non-banking growth.
The outlook for KB remains positive due to earnings growth and strategic diversification, but risks include reliance on interest income and macroeconomic sensitivity. Near-term resistance at $121 could limit upside, while support at $112 provides a cushion. Institutional holdings and dividend focus offer stability, yet investors should monitor interest rate impacts and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
